CHARLES RIVER LABORATORIES (CRL)       248.21  +4.96 (+2.04%)

248.21  +4.96 (+2.04%)

US1598641074 - Common Stock - After market: 248.21 0 (0%)


Fundamental Rating

4

Taking everything into account, CRL scores 4 out of 10 in our fundamental rating. CRL was compared to 66 industry peers in the Life Sciences Tools & Services industry. The financial health of CRL is medium. Also its profitability is quite bad. While showing a medium growth rate, CRL is valued expensive at the moment.




Profitability

Profitability Rating

3

CRL has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for CRL.
CRL's Return On Equity of 16.61% is in line with the rest of the industry. The industry average Return On Equity is 16.61%.

CRL's Return On Assets of 5.91% is worse than the rest of the industry. The industry average Return On Assets is 8.42%.
CRL has a Profit Margin of 11.54%. This is below the industry average of 16.49%.
VS Industry

ROA (5.91%) VS Industry: 30% outperformed.

0.30
57.39

ROE (16.61%) VS Industry: 50% outperformed.

1.18
180.91

Profit Margin (11.54%) VS Industry: 30% outperformed.

0.20
383.95

Valuation

Valuation Rating

3

CRL's Price/Earning Ratio is a bit cheaper than the industry average which is at 28.50.
When comparing the Enterprise Value to EBITDA ratio of CRL to the average industry ratio of 20.40, CRL is valued rather cheaply.
With a Price/Earnings Ratio of 23.33, CRL is valued on the expensive side.
With a Forward Price/Earnings Ratio of 21.49, CRL is valued rather expensively.

With a price book ratio of 4.81, CRL is valued correctly.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
Compared to an average industry price book ratio of 2.49, CRL is valued more expensive than its industry peers.
VS Industry

Price/Earnings (23.33) VS Industry: 64% outperformed.

111.87
7.60

Price/Book (4.81) VS Industry: 31% outperformed.

52.13
0.34

Enterprise Value/ EBITDA (15.97) VS Industry: 71% outperformed.

666.25
2.34

Growth

Growth Rating

5

The Earnings Per Share has been growing by 17.72% on average over the past 5 years. This is quite good.
Based on estimates for the next 5 years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.01% on average per year.
CRL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.37%.
The Revenue has been growing by 16.06% on average over the past 5 years. This is quite good.

CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.01%.
CRL is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 9.69% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS17.72% 19.72% 4.01% 6.48% 5.74% 8.62% 12.01%
Revenue16.06% 16.03% 10.37% 11.02% 8.51% 8.92% 9.69%

Health

Health Rating

4

The Piotroski-F score of CRL is 7.00. This is a strong score and indicates good health and profitability for CRL.
CRL has a Current Ratio of 1.40. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.14 indicates that CRL should not have too much problems paying its short term obligations.
CRL has an Altman-Z score of 2.71. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.

CRL has a Altman-Z score comparable to the industry average, which is at 2.71.
Compared to an average industry Current Ratio of 4.77, CRL is worse placed to pay its short term obligations than its industry peers. 84% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 4.30, CRL is worse placed to pay its short term obligations than its industry peers. 84% of its industry peers have a better Quick Ratio.
CRL has one of the worst Debt to Equity ratios in its industry. 89% of its industry peers require less debt for financing their operations.
VS Industry

Debt/Equity (1.12) VS Industry: 11% outperformed.

3.88
0.00

Quick Ratio (1.14) VS Industry: 16% outperformed.

0.04
40.60

Current Ratio (1.4) VS Industry: 16% outperformed.

0.04
40.60

Altman-Z (2.71) VS Industry: 50% outperformed.

-152.45
23.18

Dividend

Dividend Rating

0

No dividends for CRL!.

CHARLES RIVER LABORATORIES248.21

NYSE:CRL (2/1/2023, 7:07:10 PM)+4.96 (+2.04%)

After market: 248.21 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 11-02 2022-11-02/bmo Earnings (Next) 02-14 2023-02-14
Inst Owners 195.45% Inst Owner Change 0.4%
Ins Owners 0.92% Ins Owner Change 0.21%
Market Cap 12.63B Analysts 85
Price Target 271.07 (9.21%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 2.33%
Min EPS beat(2) 0.3% Max EPS beat(2) 4.37%
EPS beat(4) 4 Avg EPS beat(4) 1.57%
Min EPS beat(4) 0.26% Max EPS beat(4) 4.37%
Revenue beat(2) 1 Avg Revenue beat(2) -1.13%
Min Revenue beat(2) -3.17% Max Revenue beat(2) 0.92%
Revenue beat(4) 2 Avg Revenue beat(4) -0.49%
Min Revenue beat(4) -3.17% Max Revenue beat(4) 0.92%
PT rev (1m) -1.3% PT rev (3m) -1.94%
EPS NQ rev (1m) 0% EPS NQ rev (3m) 0.16%
EPS NY rev (1m) 0% EPS NY rev (3m) 0.85%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) 0.03%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 0.53%

Valuation
Industry RankSector Rank
PE 23.33
Fwd PE 21.49
P/S 3.34
P/FCF 45.16
P/OCF 20.56
P/B 4.81
P/tB N/A
EV/EBITDA 15.97
EPS(TTM) 10.64 EY 4.29%
EPS(NY) 11.55 Fwd EY 4.65%
FCF(TTM) 5.5 FCFY 2.21%
OCF(TTM) 12.07 OCFY 4.86%
SpS 74.32 BVpS 51.63
TBVpS -21.96 PEG (NY) 3.6
PEG (5Y) 1.32

Profitability
Industry RankSector Rank
ROA 5.91%
ROE 16.61%
ROIC 8.65%
ROICexc 8.92%
ROICexgc 22.67%
OM 17.69%
PM 11.54%
GM 37.31%
ROICexgc(3y) 22.56% ROICexcg growth 3Y 3.87%
ROICexcg growth 5Y 3.45% ROICexc(3y) 8.64%
ROICexc growth 3Y -1.33% ROICexc growth 5Y -2.11%
OM growth 3Y 4.46% OM growth 5Y 2.58%
PM growth 3Y 3.4% PM growth 5Y 3.71%
GM growth 3Y 0.56% GM growth 5Y -0.54%
F-Score 7 Asset Turnover 0.51

Health
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF 10.51
Debt/EBITDA 3.05
Cap/Depr 113.94%
Profit Quality 64.08%
Current Ratio 1.4
Quick Ratio 1.14
Altman-Z 2.71
F-Score 7 WACC 9.35%
ROIC/WACC 2.42 Cap/Depr(3y) 76%
Cap/Depr(5y) 75.48% Profit Quality(3y) 125.16%
Profit Quality(5y) 139.26%

Growth
EPS 1Y 4.01% EPS 3Y 19.72%
EPS 5Y 17.72% EPS growth Q2Q -2.59%
EPS Next Y 6.48% EPS Next 2Y 5.74%
EPS Next 3Y 8.62% EPS Next 5Y 12.01%
Revenue growth 1Y 10.37% Revenue growth 3Y 16.03%
Revenue growth 5Y 16.06% Revenue growth Q2Q 10.4%
Revenue Next Year 11.02% Revenue Next 2Y 8.51%
Revenue Next 3Y 8.92% Revenue Next 5Y 9.69%
EBIT growth 1Y 15.25% EBIT growth 3Y 21.2%
EBIT growth 5Y 19.05% EBIT Next Year 39.93%
EBIT Next 3Y 19.44% EBIT Next 5Y 15.68%
FCF growth 1Y -37.34% FCF growth 3Y 21.41%
FCF growth 5Y 15.44% OCF growth 1Y 4.3%
OCF growth 3Y 20.26% OCF growth 5Y 19.3%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA